China updates drug reimbursement list, agrees price cuts

Drugs added include AbbVie's Humira and Roche's Perjeta. Chinese regulators have added 70 new medicines to the country’s National Reimbursement Drug List (NRDL), and has agreed an average ... The key drugs which have been added to the list include

AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER

According to ICER, this evidence demonstrates that Rinvoq provides a small to substantial health benenfit over Humira. ... However, the institute still concluded that Rivoq “provides marginal clinical benefit in comparison to Humira at higher costs”.

Global Medical Affairs as CATALYSTs for Change

AbbVie, whilst still marketing HUMIRA had to prepare to launch its new asset, SKYRIZI. ... HUMIRA was the day‐to‐day focus, but medical teams need to advance and learn – CATALYST was the solution.

AbbVie sells $30bn of bonds ahead of Allergan merger

Any remaining proceeds will be used for ‘general corporate purposes’. The acquisition of Allergan was due largely to the impending US patent expiry of $20bn-a-year blockbuster Humira. ... Although biosimilar versions of Humira won’t hit the US

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]